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Tumor suppressor TP53 gene is one of the most 
widely studied human genes. P53 protein plays a criti-
cal role in a cell cycle control, apoptosis initiation and 
DNA repair, controlling genome stability in the response 
to genotoxic factors. The choice of the p53 response is 
thought to depend on the strength of the stress signal 
and cellular damage extent. Mutations in TP53 gene are 
the most frequent genetic alterations in human cancer, 
including lung cancer. Functional inactivation of p53 ow-
ing to carcinogen-induced mutations in DNA-binding 
domains results in transcriptionally inactive p53, which 
is not capable to efficiently protect against cell damage.
Smoking is the main lung cancer risk factor, and sev-
eral mutations in TP53 have been found to be specific 
lung cancer associated hotspot, induced by cancerous 
tobacco-derived metabolities [1]. Besides the common 
mechanisms that alter p53 function, TP53 gene polymor-
phisms are considered to be the risk factor for malignant 
disease, contributing to a person’s propensity to carci-
nogenic exposure as well as disease progression and/
or modulation of therapeutic outcome. There are about 
400 known polymorphisms for TP53 gene described 
in literature [2]. One of them, Arg72Pro (Ex4+119G>C, 
rs1042522) is the most well-known due to its ability to 
noticeably affect p53 function. A common polymorphism 
at codon 72 of TP53 results in either an arginine residue 
(TP53Arg) or proline residue (TP53Pro). Data on functional 
studies suggest that Arg and Pro allele variants are not 
biochemically equivalent because they affect p53 ability 
to bind DNA and interact with regulatory and target genes 
for activating repair or apoptosis processes in response 
to stress stimuli. TP53Pro variant has been shown to 
transcriptionally activate several p53 dependent genes 
involved in DNA repair better than the TP53Arg form, 
resulting in more effective DNA repair. TP53Arg in turn 
is capable of inducing apoptosis better than TP53Pro 
expressing variant [3]. Case-control studies suggested 
that codon 72 polymorphism of TP53 modulates the sus-
ceptibility of carriers to various malignancies including lung 
cancer (LC), but obtained data are controversial [2, 4–7].
Polymorphisms in TP53 gene introns 3 (rs17878362) 
and 6 (rs1625895) are associated with gene expression 
level by controlling mRNA stabilization [4, 8, 9]. X-ray repair 
cross-complementing group 1 (XRCC1) gene is required 
for the efficient repair of single-strand breaks and dam-
aged bases of DNA. Base excision repair (BER) system is 
closely interrelated to p53 function [10]. Single nucleotide 
polymorphism in XRCC1 exon 10 (rs2548) results in the 
substitution Arg to Gln leading to the decrease of BER 
efficiency [11]. According to Human Genome Epidemiol-
ogy Review the XRCC1 399Gln/399Gln genotype was 
associated with increased risk of tobacco-related cancers 
among light smokers but decreased risk among heavy 
smokers [12]. This unexpected result could be explained 
by enhanced apoptosis of cells with increased DNA dam-
age from heavy tobacco smoking, which is the indirect 
suggestion to probable «crosstalk» between TP53 and 
XRCC1 polymorphisms.
Ageing is one of the most important risk factor of LC 
due to affecting the repair and immune system functions 
under the long deleterious exposures. P53 is able to 
induce cell cycle arrest and/or apoptosis in response to 
many stress stimuli that provides replicative senescence 
suppressing the development of cancer. Cell senes-
cence is maintained by p53 and is able to be reversed 
following p53 inactivation [13]. Senescent cells have 
the phenotype entailed functional changes that can 
alter tissue structure and function that characterize 
aging. Thus tumor suppressor gene TP53 has both anti-
cancer and pro-aging effects, depending on the age of 
the organism [14]. To our knowledge hitherto there are 
few studies devoted to the evaluation of the influence 
of TP53 polymorphism on age-related cancer [14–16]. 
To further define the role of the TP53 polymorphism in 
the view of «cross-talk» betweenTP53 and DNA-repair 
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involving genes in LC risk we examined the influence of 
combined genotypes of TP53 (exon 4, intron 3, intron 
6) and XRCC1 (codon 10) on LC age of onset.
MATERIALS AND METHODS
Patients. 136 primary non small cell lung cancer 
(NSCLC) patients collected from 2000 to 2004 at the 
Tomsk Cancer Research Institute Clinic were included in 
this study. Studies were performed according to the rules 
of Cancer Research Institute Ethical Committee. Patients 
mean age was 60.2 ± 8.6 (age range 42-79). All patients 
had a treatment including neoadjuvant chemotherapy 
and surgery. Tumors were staged according to the tumor 
node metastasis (TNM) classification of malignant tumors 
T1-4N0-2M0. 196 healthy individuals from the same 
region adjusted for age and sex were used as controls.
Samples. Peripheral blood was obtained from all 
LC patients and healthy donors. DNA was isolated from 
blood cells using chlorophorm/phenol extraction fol-
lowed by ethanol precipitation according to the standard 
procedure [17].
Methods. TP53 polymorphisms in codon 72 of exon 
4 (Arg72Pro), in intron 3 (16 bp duplication), in intron 
6 (G/A transition, Mcp1) and XRCC1 polymorphism in 
codon 10 (Arg399Gln) were analyzed with Restriction 
Fragment Lenth Polymorphism PCR. Primer sequences 
for TP53 codon 72 exon 4 were 5′–CTGGTAAGGA-
CAAGGGTTGG–3′ and 5′–ACTGACCGTGCAAGTCA-
CAG-3′, for exon 3 were 5′-TGGGACTGACTTTCT-
GCTCTT-3′ and 5′–TCAAATCATCCATTGCTTGG–3′, for 
exon 6 were 5′–TGGCCATCTACAAGCAGTCA–3′ and 
5′-TTGCACATCTCATGGGGTTA-3′. Primer sequences for 
XRCC1 codon 10 were 5′–GCCCCGTCCCAGGTAAG–3′ 
and 5′-AGCCCCAAGACCCTTTCACT-3′.
Statistics Deviation from Hardy Weinberg equilibrium 
of the polymorphisms under study were determined using 
Chi-square test. Cross tabulation and Chi-square test were 
performed when studying of association between differ-
ent polymorphisms. Pearson Chi-square test or Fisher’s 
exact test were used when appropriate, and statistical 
significance level <0.05 was considered. Overall survival 
was computed and compared using Kaplan-Meier test. 
Computation was performed using STATISTICA 6.0.
RESULTS
Several main aspects, including polymorphism in 
TP53 gene exons and introns, «cross-talk» between the 
different gene polymorphisms, age dependence of lung 
cancer and TP53 antagonistic pleiotropism were taken 
into consideration in this study. The case and control 
groups were both genotyped for TP53 and XRCC1 poly-
morphisms, which were shown to be in Hardy-Weinberg 
equilibrium (data not shown).
First, we analyzed the distribution of each TP53 poly-
morphism genotypes among controls and LC patients. To 
assess LC risk-age relation, all LC patients were divided 
into 2 groups: 40-59 years old (54%, younger) and 60-
79 years old (46%, elderly) according to WHO recom-
mendations (1963).
The distribution of the three TP53 genotypes in the 
whole group of LC patients was similar to those of the 
controls. There was statistically significant difference 
in the prevalence of each polymorphism when strati-
fied on smoking and age. We have revealed the higher 
frequency in w/m genotype at TP53 intron 6 (29% vs. 
15% in controls, p<0.001) and Arg/Pro polymorphism 
at exon 4 (54% vs. 43% in control, p<0.000) in smoking 
younger LC patients in comparison with control. As to 
TP53 polymorphism at intron 3, only the trend to increas-
ing frequency of heterozygote was shown in LC younger 
smokers as compared with control (data not shown).
To further define the role of the TP53 polymorphism in 
LC risk we examined the influence of combined genotypes 
of TP53 (intron 3, exon 4, intron 6) on LC age of onset. 
We analyzed the frequencies of combined either wild (i.e. 
w/w, Arg/Arg, w/w) or variant (i.e. w/m, Arg/Pro, w/m) 
TP53 genotype among cases and controls. Modifying 
effect of XRCC1 polymorphism in codon 10 towards asso-
ciation of TP53 genotype and LC was also examined under 
the condition of smoking. Among genotyped 196 controls 
the most frequent combinations of TP53 gene genotypes 
were w/w-Arg/Arg-w/w (wild genotype combination, 
38%), w/w-Arg/Pro-w/w (4 exon heterozygote, 29%) and 
w/m- Arg/Pro-w/m (heterozygous genotype combination, 
4%). Whereas in total LC group of patients these combina-
tions occurred in 51% (p<0.05 vs. control), 21% and 13% 
(p<0.05 vs. control), respectively. Further we have evalu-
ated the frequency of different genotypes combinations in 
LC patients stratified by smoking and age. No significant 
differences in the distribution of homozygous wild (major) 
genotype combination between younger LC patients and 
control were found (Table 1).
Table 1. Distribution of p53 exon 4-intron 3-intron 6 genotype combina-
tion among younger and elderly non small cell lung cancer patients
Combination of p53 
(3-intron-4 exon-6 in-
tron) genotypes
Healthy indi-
viduals
NSCLC patients
Younger (40–59) Elderly (60–79)
Frequency of genotypes,%
w/w-Arg/Arg-w/w 38 (74/196) 38 (23/61) 62*,# (46/74)
p < 0.000,
p < 0.00
w/w-Arg/Pro-w/w 29 (57/196) 23 (14/61) 20 (15/74)
w/dup16- Arg/Pro-w/m 4 (8/196) 18*,# (11/61)
p < 0.000
p = 0.08
8 (6/74)
Note: *significant differences compared with the control group; #significant 
differences compared with the elderly NSCLC patients group
We found the higher frequency in heterozygous w/m-
Arg/Pro-w/m TP53 genotype combination in younger 
smokers (21% vs. 4% in controls, p<0.05) (Table 2). The 
same association was seen for TP53 genotype combina-
tion with Arg/Gln XRCC1 genotype (21 vs. 3% in control, 
p<0.05). So, heterozygous genotype combination was 
associated with NSCLC in younger smoking individuals. 
However, no increased LC risk was found for younger 
individuals carrying wild Arg/Arg XRCC1 genotype in 
combination with variant TP53 genotype (36% vs. 37% 
in control).
Table 2. Distribution of p53 exon 4-intron 3-intron- 6 genotype combination 
among younger and elderly non small cell lung cancer patients stratified by smoking
Group of examine patients Frequency of genotypes
Healthy individuals w/w-Arg/Arg-w/w w/dup16-Arg/Pro-w/m
Younger NSCLC patients
Smokers 34 (16/47) 21* (10/47)
Never smokers 80* (4/5) 0
Elderly NSCLC patients
Smokers 68* (25/37)
p < 0.000
11 (4/37)
Never smokers 53 (7/13) 0
Note: *significant differences compared with the control group
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We performed wild TP53 genotypic combination 
analyses in elderly individuals and found its significant 
elevation in comparison with control group (62% vs. 
38% in controls, p<0.05), but no modifying effect of 
smoking or XRCC1 genotype (4% in LC cases and con-
trols) was found (Table 1, 2). In contrast to younger 
LC patients, no differences in the frequency of het-
erozygous TP53 genotype combination as well as its 
combination with XRCC1 heterozygotes was revealed in 
elderly LC individuals. Thus our findings point the asso-
ciation of major TP53 genotypes combination with LC in 
elderly individuals but smoking as well as XRCC1 gene 
polymorphism do not affect this risk factor significance.
Next we determined whether the different TP53 gen-
otype combination was associated with overall survival 
of LC patients who were under follow-up for 52 months 
after cancer diagnosis. The cumulative 3-year survival 
was reduced in carriers of wild TP53 genotype vs. those 
patients with heterozygous TP53 genotype (survival 
rate was 83% vs. 57%, respectively, p<0.05) (Figure).
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Figure. Kaplan-Meier estimated overall survival of LC patients with 
different combinations of TP53 genotypes (Arg72Pro ex4, dup16 in3, 
Mcp1 in6 polymorphism). Continuous blue curve — TP53 gene 
w/w-Arg/Arg-w/w genotype combination; broken red curve — 
TP53 gene w/m- Arg/Pro-w/m genotype combination; + — censored 
observation
DISCUSSION
Thus we found that TP53 polymorphisms in exon 
4 and intron 3 and 6 are associated with LC in younger 
smoking individuals, suggesting the functional effect 
for intronic polymorphism in LC, reported by others 
[4, 8]. Despite the belief that introns are nonfunctional 
because they do not code the proteins, evidences 
exist indicating intron-regulated mRNA expression 
and coding-region mutations [4].
Although one variant single nucleotide polymorphism 
is found to have the influence on the disease, probably 
«crosstalk» between gene polymorphisms in the same 
pathway may provide a more accurate examination of LC 
risk [5]. In current study we tested the interactive effect 
of polymorphisms in TP53 exon 4, intron 3 and 6 and 
XRCC1 exon 10 on LC risk in individuals of different 
age. The main findings in this report are that combined 
analysis of TP53 and XRCC1 variant alleles showed the 
association of variant genotype combination with NSCLC 
in younger smoking individuals and, in contrast, that 
combination of wild genotypes increases LC risk in elderly 
patients independently of smoking factor.
The increase in heterozygous TP53 genotype com-
bination frequency in younger smokers reflects the 
prevalence of variant alleles for each studied TP53 poly-
morphism, indicating their important effect on LC onset. 
Wu et al. [4] previously reported that patients with Pro/
Pro genotype were diagnosed with LC at an earlier age 
and were heavy smokers in contrast to patients with 
Arg allele in TP53 genotype. We provided the evidence 
of interplay between TP53, XRCC1, age and NSCLC. 
Our data suggesting that variant Pro allele of TP53 
(Arg72Pro polymorphism) increases LC risk in younger 
smokers whereas wild allele Arg promotes LC in elderly 
person, which is in accordance with tumor suppressors’ 
antagonistic pleioptropy hypothesis [14].
P53 is known to be able to induce the senescence 
response to many DNA-damaging stimuli as well as on-
cogene expression. Activation of p53 in response to DNA 
damage usually leads to either proper repair of the injuries 
or elimination of the damaged cells from the proliferative 
cell pool [18]. There are several potential cellular out-
comes, which are affected by cell type and DNA lesion 
severity. Transient arrest and proper repair occur when 
DNA lesions are not heavy and the repair is possible, and 
this outcome is the most favorable for cell and organism. 
Taking into account that TP53 Pro allele is more efficient 
than Arg allele in inducing G1 arrest, specifically activating 
p53-dependent target genes responsible for DNA repa-
ration resulting in the effective maintenance of genomic 
stability [3], we can suppose its benefit to reach favorable 
outcome in response to stress stimuli. Apoptosis is realized 
when the damage is very severe, due to p53-dependent 
transcriptional up-regulation of apoptotic effectors, such 
as PUMA, NOXA, BAX, and down-regulation of apop-
totic repressors, such as BCL-2 and survivin. Preferential 
activation of PUMA and NOXA by TP53 Arg variant may 
contribute to more effective apoptosis induction [19]. 
Apoptosis prevents cancer by eliminating cells that are 
damaged or otherwise potentially oncogenic. Because 
apoptosis irreversibly removes cells from tissue, Arg allele 
can promote tissue depletion and organ degeneration. 
Senescent cells have been shown to accumulate with 
age in vivo and this is accompanied by several dramatic 
changes, best characterized for fibroblasts, which are as 
cells maintaining the stroma and regulating epithelial tis-
sue function [18]. Senescent human fibroblasts acquire 
the secretory phenotype characterized by increased 
secretion of extracellular matrix remodeling enzymes, 
inflammatory cytokines and epithelial growth factors [14]. 
These functional changes in senescent cells may pro-
gressively promote aging related decline in structure and 
function, providing tumor stimulated microenvironment 
in aging organisms. Senescent stromal cells can stimulate 
the growth and promote the acquisition of invasive and 
migratory phenotypes by normal or premalignant epithelial 
cells possibly by epithelial-mesenchimal transition [20].
The age dependence of LC development could be 
explained by the accumulation of mutations, but evi-
dences exist that cells with oncogenic mutations also 
require a permissive tissue microenvironment in which 
to progress into a malignant tumor. The age dependent 
accumulation of senescent stromal cells may synergize 
with the age-dependent accumulation of mutations, 
resulting in the rise of epithelial cancer.
In our case smoking carriers of TP53 gene Pro allele 
(Arg72Pro polymorphism), which codes p53 protein that 
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weakly induce apoptosis, are thought to have excessive 
mutation accumulation promoting neoplastic transfor-
mation in younger persons. Variant alleles of TP53 gene 
with intronic polymorphisms as well as polymorphism of 
XRCC1 gene in codon 10 contribute to tumor develop-
ment because tumor cells are not efficient enough in 
TP53 gene expression and DNA repair.
As for older individuals, Arg allele protecting from 
cancer in early period of life can provide accelerated 
ageing resulting in the establishment of senescent mi-
croenvironment that is able to promote tumor develop-
ment and progression under the condition of age-related 
mutation accumulation. Wild genotypes of TP53 gene 
with intron 3 and intron 6 polymorphisms are expected 
to provide the high expression of Arg allele enhancing its 
deleterious effect.
The data presented in this study suggest that Arg/Pro 
genotype is beneficial for LC cancer patient survival in 
contrast to Arg/Arg genotype. Orsted et al.  also demon-
strated that overall 12-year survival was higher for Pro/Pro 
carriers compared to Arg/Arg carriers in large scale study 
of Danish population [16]. It should be noted that disease 
outcome is strongly dependent on the therapeutic mo-
dality and tumor sensitivity to chemo- or radiotherapy. 
P53-dependent apoptosis is an important mechanism 
through which DNA-damaging anticancer agents exert 
their biological effect [19]. We have earlier reported that 
Arg/Pro TP53 gene genotype (Arg72Pro polymorphism) 
was associated with better tumor response to neoadju-
vant chemotherapy in LC patients [21]. There are few 
other studies on association of TP53 codon72 polymor-
phism with clinical tumor response to anticancer drugs, 
which are rather controversial [19, 22, 23].
CONCLUSION
Our findings provide evidence of interplay between 
TP53, XRCC1, age and cancer. We have shown the evi-
dences for the interaction of exon and intron TP53 gene 
polymorphisms and LC risk. Obtained data indicate that 
combination of TP53 and XRCC1 variant genotypes is 
associated with the increased LC risk in smoking younger 
individuals. In contrast, major allele combination increas-
es LC risk for individuals over the age of 60. Our data are 
in accordance with the antagonistic pleiotropy hypothesis 
indicating that p53 can protect organism from cancer 
early in life but promoting aging phenotypes, including 
late life cancer, in older organisms [10].
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